---
id: 211
title: Genital Ulcer Disease (GUD)
category: clinical_syndromes
subcategory: sexually_transmitted
tags: [STI, HSV, syphilis, chancroid, LGV, genital-ulcer]
difficulty: medium
---

## Question

How is genital ulcer disease evaluated? Use **"HSV (Painful, Vesicles) vs Syphilis (Painless, Indurated) vs Chancroid (Painful, Purulent), Test All, Treat Empirically"** framework.

## Answer

### **Differential Diagnosis:**

**Common (US):**
- **Herpes simplex virus (HSV-1/2)** - MOST COMMON in US (>50%)
- **Syphilis** (*Treponema pallidum*) - increasing incidence
- **Chancroid** (*Haemophilus ducreyi*) - rare in US, common in developing countries

**Less Common:**
- **Lymphogranuloma venereum (LGV)** (*Chlamydia trachomatis* L1-L3)
- **Granuloma inguinale (Donovanosis)** (*Klebsiella granulomatis*)

**Non-Infectious:**
- **Behçet disease, fixed drug eruption, trauma**

### **Clinical Features:**

| **Pathogen** | **Ulcer Characteristics** | **Pain** | **Lymphadenopathy** | **Key Features** |
|--------------|---------------------------|----------|---------------------|------------------|
| **HSV** | Multiple, shallow, vesicular → ulcerative | **PAINFUL** | Bilateral, tender | Grouped vesicles, recurrent |
| **Syphilis** | Single (usually), clean base, indurated border | **PAINLESS** | Bilateral, non-tender, firm | "Chancre" - firm, rubbery |
| **Chancroid** | Multiple, ragged borders, purulent base | **VERY PAINFUL** | Unilateral, tender, may suppurate | "Soft chancre," autoinoculation |
| **LGV** | Small, transient ulcer (often missed) | Variable | **Unilateral**, VERY tender, fluctuant, may form fistulas | Proctocolitis if receptive anal intercourse |
| **Granuloma inguinale** | Beefy red, painless, progressive | Painless | **NO adenopathy** (pseudobuboes = subcutaneous granulomas) | Rare in US |

### **Diagnostic Approach:**

**Test ALL Patients for:**
- **HSV PCR/culture** (from ulcer base, swab)
- **Syphilis serology:** RPR/VDRL + treponemal test (FTA-ABS, TP-PA)
- **Darkfield microscopy or PCR** (if available, for *T. pallidum*)
- **HIV testing** (genital ulcers ↑HIV transmission/acquisition)

**If Suspected LGV or Chancroid:**
- **LGV:** *C. trachomatis* NAAT from ulcer/lymph node aspirate (+ request genotyping for L1-L3)
- **Chancroid:** Culture on specialized media (difficult, often clinical diagnosis)

**Biopsy:**
- **If atypical, chronic, or non-healing** (r/o malignancy, granulomatous disease)

### **Treatment:**

**Empiric Treatment (Before Results Available):**

**If Presentation Suggests HSV:**
- **Valacyclovir 1g PO BID × 7-10 days** (first episode)
- **Valacyclovir 500mg PO BID × 3 days** (recurrent)

**If Chancroid or Syphilis Suspected (Risk Factors, Endemic Area):**
- **Ceftriaxone 250mg IM × 1** (covers chancroid, early syphilis)
- **+ Azithromycin 1g PO × 1** (covers chancroid, *Chlamydia*)

**Pathogen-Specific Treatment:**

**HSV (Primary or Severe Recurrent):**
- **Valacyclovir 1g PO BID × 7-10 days**
- **Acyclovir 400mg PO TID × 7-10 days**
- **Famciclovir 250mg PO TID × 7-10 days**
- **Suppression** (if ≥6 recurrences/year): Valacyclovir 500mg-1g PO daily

**Syphilis (Primary):**
- **Benzathine penicillin G 2.4 million units IM × 1** (single dose)
- **PCN allergy:** Doxycycline 100mg PO BID × 14 days OR ceftriaxone 1-2g IV/IM daily × 10-14 days

**Chancroid:**
- **Azithromycin 1g PO × 1** (single dose, preferred)
- **Ceftriaxone 250mg IM × 1**
- **Follow-up in 3-7 days** (ulcers should improve within 7 days)

**LGV:**
- **Doxycycline 100mg PO BID × 21 days** (MUST be 21 days, NOT 7 days like routine *Chlamydia*)
- **Alternative:** Azithromycin 1g PO weekly × 3 weeks

**Granuloma Inguinale (Donovanosis):**
- **Azithromycin 1g PO weekly OR 500mg PO daily × ≥3 weeks** (until lesions heal)
- **Doxycycline 100mg PO BID × ≥3 weeks**

### **Co-Infection and HIV:**

**Test All for HIV:**
- **Genital ulcers ↑HIV transmission** (2-5× risk)
- **HIV ↑severity** of HSV (larger, slower healing)

**Co-treatment:**
- **Treat all identified infections**
- **Consider empiric syphilis treatment** if high prevalence area

### **Follow-Up:**

**Re-examine in 7 Days:**
- **Ulcers should be improving**
- **If not:** Consider treatment failure, co-infection, HIV, malignancy

**Partner Notification:**
- **All recent sexual partners** (60 days for HSV/syphilis, 10 days for chancroid)

### **Special Situations:**

**HIV-Positive Patients:**
- **HSV:** May need higher doses, longer duration, IV acyclovir if severe
- **Syphilis:** Same treatment, but close serologic follow-up (risk of neurosyphilis)

**Pregnancy:**
- **HSV:** Acyclovir/valacyclovir safe
- **Syphilis:** Benzathine PCG (MUST treat, prevents congenital syphilis)
- **Chancroid/LGV:** Azithromycin OR ceftriaxone (avoid doxycycline)

**Proctocolitis (Receptive Anal Intercourse):**
- **Consider LGV** (doxycycline × 21 days)
- **Also test for:** HSV, syphilis, gonorrhea, *Chlamydia*

## Key Points

### **HSV = Most Common (US):**
- **Painful, multiple, vesicular → shallow ulcers**
- **Treatment:** Valacyclovir 1g BID × 7-10 days (first episode)

### **Syphilis = Painless Chancre:**
- **Single, indurated, firm border**
- **Treatment:** Benzathine PCG 2.4 million units IM × 1

### **Chancroid = Painful, Purulent:**
- **"Soft chancre," ragged borders**
- **Treatment:** Azithromycin 1g PO × 1 OR ceftriaxone 250mg IM × 1

### **LGV = Tender Lymphadenopathy:**
- **Small transient ulcer + unilateral tender inguinal LN**
- **Treatment:** Doxycycline 100mg BID × **21 days** (NOT 7!)

### **Test All for HIV:**
- **Genital ulcers ↑HIV transmission 2-5×**

### **Clinical Pearls:**
- **HSV:** Painful, vesicles → ulcers (valacyclovir 1g BID × 7-10d)
- **Syphilis:** Painless, indurated chancre (benzathine PCG 2.4M units IM × 1)
- **Chancroid:** Very painful, purulent (azithromycin 1g × 1)
- **LGV:** Proctocolitis + unilateral tender LN (doxycycline × **21 days**)
- **Test all for:** HSV, syphilis, HIV
- **Empiric treatment:** Consider if high suspicion, endemic area

## Sources

- [CDC: Sexually Transmitted Infections Treatment Guidelines 2024]
- [IDSA: Genital Ulcer Disease 2024]

## Media

N/A
